Orgenesis Inc. announced the appointment of Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies. Before joining Orgenesis, Carmer led the US Specialty Care Division of AstraZeneca, and had responsibility for the company's portfolio of specialty care biopharmaceutical products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4924 USD | +7.00% | +2.56% | -1.66% |
05-20 | Orgenesis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | North American Morning Briefing : Powell Comments, -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-1.66% | 15.69M | |
-7.89% | 177B | |
-1.03% | 108B | |
-7.49% | 65.55B | |
+3.29% | 50.66B | |
+5.59% | 42.58B | |
+5.73% | 40.74B | |
+17.81% | 31.07B | |
+16.57% | 25.45B | |
-4.20% | 23.93B |
- Stock Market
- Equities
- ORGS Stock
- News Orgenesis Inc.
- Orgenesis Inc. Appoints Scott Carmer as CEO of North American Subsidiary